speb/financial-data huggingface dataset:
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 1321193778.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 1321193778.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 5518000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 5518000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 461500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 461500000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 621600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 621600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 29386400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 29386400000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Investments: 443000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Investments: 443000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 3680600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: -200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: -200000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 1756100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1756100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 756500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 420300000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 10382700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 6260900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 1475000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 1475000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 250600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 250600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 652300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 652300000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 228900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 228900000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: -14400000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 16812700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 16812700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2530000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 2530000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 5254800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 5254800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 4146400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 2728000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 87000000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -18850300000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -6643800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 10917800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 10917800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 35721300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 9549800000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 8163400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 2427600000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 329100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 329100000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -10645100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Research And Development: 971300000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 1324800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 1324800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 10493200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 10493200000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 20040900000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 52500000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 3492700000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 6054600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 1325748130.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 1325748130.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: -487100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 480000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 81254100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 81254100000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 40385600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 40385600000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -118980000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: 3235100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 1193000000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 63600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 63600000.00
PPLPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -3343600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 156775900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 156775900000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 113394800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 113394800000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 48564700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 48564700000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 81254700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 81254700000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 83823500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 24358400000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 75521200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 75521200000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 98806000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 98806000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 37858500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 37858500000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 36600000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 96100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 96100000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -396600000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -396600000.00
PPLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 4554352.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 4554352.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Work In Process: 6239000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 6239000000.00
PPLPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 20307200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 20307200000.00
PPLPHARMA.NS income_statement (annual, 2025-03-31) — Write Off: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 13302400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 19337100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 1317741935.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: -0.62
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 6940500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 1972800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 1972800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 1317741935.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.62
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 71300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 2044100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 12396600000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 861500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 861500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -817000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -861500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -861500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 1836700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: -962180000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: -905800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 19337100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 584000000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 5143700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Special Charges: -207400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: -790200000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 6940500000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 1972800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 207400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 62220000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 26800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 20242900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 207400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 207400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 53700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 13705700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 21398700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 1322233010.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: -1.03
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 7863100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 2127400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 2127400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 1322233010.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: -1.03
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: -46200000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 2081200000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 13535600000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 892400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 892400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -1361900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -892400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -892400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 2500900000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: -1068110000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: -170100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 21398700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 432400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 5579800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 419700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: -938600000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 7863100000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 2127400000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -419700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -125910000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 423300000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 21568800000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -419700000.00
PPLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -419700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 50202800000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 14539700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 87588200000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 27517700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 24791100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 24791100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 21576700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 21576700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -35196600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -35196600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 47683000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 47683000000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -959100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -959100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 403300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 403300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 1325357599.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 1260000000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Basic EPS: -2.46
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: -0.07
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 1823200000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 23781800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 23781800000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -8900200000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 1791100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1791100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 13271600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 13271600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 11998800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 11998800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 13348300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 13348300000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -185500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 2250300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 2250300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 9748500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 9748500000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -7980900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -218900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 3189400000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 7780200000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 2171900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 5265600000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 7875800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 13271600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 13271600000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Dividend Paid: -185500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 81625800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 81625800000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 28100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 7991700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 7991700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 35836300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 10556700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 71916600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 71916600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 436800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 436800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 11955000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 11955000000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 12391800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 12391800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Deferred Taxes Liabilities: 105500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Deferred Taxes Liabilities: 105500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 47582800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 47582800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 422100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 422100000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 8312400000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 8312400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 8312400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 2183800000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 8312400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 2183800000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 1332085105.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 1260000000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Diluted EPS: -2.46
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.07
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -88200000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 399700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 1622900000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 1259900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 9935300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 3443700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 63500000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 9762600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 607700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 607700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -389800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 7522300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 7522300000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 7625700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -191600000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -22300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 2624900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill: 12574300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 12574300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 41418900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 41418900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 22535800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 22535800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 91615200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 91615200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Gross Profit: 51751900000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 16961000000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 5500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 5500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 1866400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 1758200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense: 3383500000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 829900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 3383500000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 829900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Income: 70700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 70700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -3062000000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 55900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Inventory: 30644400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 30644400000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 136580500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 136580500000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -8260300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 607700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 607700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentsin Associatesat Cost: 2442400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentsin Associatesat Cost: 2442400000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 28100000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 9026400000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 4638500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 4638500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 1354300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 1354300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 42999700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 42999700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 44354000000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 44354000000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 9026400000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -15669900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 2442400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 2442400000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 943100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 943100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 55134400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 55134400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Minority Interests: 0.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 28100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Debt: 42955900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 42955900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 1842800000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income: -88200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -88200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -88300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -88200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -88200000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: -2332600000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: -3259400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -88300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Interest Income: -3337300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -829900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 49900000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 3204000000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -6643500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -3337300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -829900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 56418600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 56418600000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -8765800000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 9847500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 40206900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 40206900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 1562500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 1562500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 5147300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 5147300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3581800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3581800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 1670400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 1670400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 12312200000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 5201400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Normalized Income: -1833260000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 966420000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 16525900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Operating Income: 1549100000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 2421300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 87588200000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 27517700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 1324744010.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 1324744010.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: 100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 843100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 843100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 727900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 727900000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 28844600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 28844600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Investments: 607700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Investments: 607700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 5059000000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: -100000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: -100000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 1562500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 1562500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 1329300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 460600000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 10846600000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 6495700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Payable: 2326600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 2326600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 68800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 68800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 961800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 961800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 1349500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 1349500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Other Special Charges: 599000000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: -500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Payables: 27117700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 27117700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1730700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1730700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 5142200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 5142200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Pretax Income: -1760600000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 430000000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: -248600000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -9916800000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -8900200000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 16556700000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 16556700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 35836300000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 10556700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 8312400000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 2183800000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 325400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 325400000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -15669900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Research And Development: 1113700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 237600000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 237600000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 6919300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 6919300000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 9966700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 134400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 3890600000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 6515500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 1329248130.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 1329248130.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Special Income Charges: -2584200000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -1757700000.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 417200000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 81625800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 81625800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 40206900000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 40206900000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -950760000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -703080000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Provision: 1498800000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 518300000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.40
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 0.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 0.00
PPLPHARMA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -2101500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 179650400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 179650400000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 124625500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 124625500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 56745800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 56745800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 81626200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 81626200000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Total Expenses: 86039100000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 25096400000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 98024200000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 98024200000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 107733800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 107733800000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 50441400000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 50441400000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 24500000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 105500000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 105500000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -2376900000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -1757700000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -2376900000.00
PPLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -1757700000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 4504120.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 4504120.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Work In Process: 6565300000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 6565300000.00
PPLPHARMA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 24333800000.00
PPLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 24333800000.00
PPLPHARMA.NS income_statement (annual, 2026-03-31) — Write Off: 118800000.00
PPM.AX balance_sheet (annual, 2021-12-31) — Accumulated Depreciation: -300000.00
PPM.AX balance_sheet (annual, 2021-12-31) — Cash Financial: 1309200000.00
PPM.AX cash_flow (annual, 2021-12-31) — Common Stock Issuance: 488200000.00
PPM.AX income_statement (annual, 2021-12-31) — Impairment Of Capital Assets: 300000.00
PPM.AX cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 488200000.00
PPM.AX balance_sheet (annual, 2021-12-31) — Leases: 2700000.00
PPM.AX balance_sheet (annual, 2021-12-31) — Long Term Equity Investment: 20800000.00
PPM.AX cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: -219500000.00
PPM.AX cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 488200000.00
PPM.AX income_statement (annual, 2021-12-31) — Net Income Discontinuous Operations: 182200000.00
PPM.AX cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: -4000000.00
PPM.AX cash_flow (annual, 2021-12-31) — Net Other Financing Charges: 913000000.00
PPM.AX cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -32800000.00
PPM.AX income_statement (annual, 2021-12-31) — Occupancy And Equipment: 1000000.00
PPM.AX balance_sheet (annual, 2021-12-31) — Ordinary Shares Number: 439500000.00
PPM.AX cash_flow (annual, 2021-12-31) — Purchase Of Investment: -4000000.00
PPM.AX cash_flow (annual, 2021-12-31) — Sale Of Business: -219500000.00
PPM.AX income_statement (annual, 2021-12-31) — Special Income Charges: -300000.00
PPM.AX income_statement (annual, 2021-12-31) — Total Unusual Items: -300000.00
PPM.AX income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: -300000.00
PPM.AX income_statement (annual, 2022-12-31) — +Total Revenue: 427800000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Accounts Payable: 13400000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Accounts Receivable: 10300000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -6800000.00
PPM.AX income_statement (annual, 2022-12-31) — Amortization: 13300000.00
PPM.AX income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 13300000.00
PPM.AX income_statement (annual, 2022-12-31) — Basic Average Shares: 439600000.00
PPM.AX income_statement (annual, 2022-12-31) — Basic EPS: 0.32
PPM.AX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 1309200000.00
PPM.AX cash_flow (annual, 2022-12-31) — Capital Expenditure: -10200000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Capital Stock: 729600000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 1243600000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Federal Funds Sold: 1243600000.00
PPM.AX cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -63300000.00
PPM.AX balance_sheet (annual, 2022-12-31) — Cash Financial: 1243600000.00
PPM.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 2319900000.00
PPM.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -87600000.00
PPM.AX cash_flow (annual, 2022-12-31) — Cash Flowsfromusedin Operating Activities Direct: -2297900000.00
PPM.AX cash_flow (annual, 2022-12-31) — Changes In Cash: -65600000.00